Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug gel fade melasma? small study pits metformin against standard cream

NCT ID NCT07345507

Symptom relief Sponsor: Jinnah Postgraduate Medical Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a 30% metformin gel applied nightly can reduce melasma (dark patches on the face) as well as a standard triple cream containing hydroquinone, tretinoin, and a steroid. Thirty-four adults with melasma used one of the two treatments plus sunscreen for 12 weeks. Researchers measured how much the melasma improved and tracked side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin gel 30% and triple combination cream (hydroquinone 2%, tretinoin 0.025%, fluocinolone acetonide 0.01%)
What this could lead to
If metformin gel works as well as the standard triple cream, it could offer a simpler, possibly cheaper option for treating melasma.
What could go wrong
This is a very small study (34 people) in one city, so results may not apply broadly. Also, metformin gel at 30% may cause skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

34 people

The number who actually took part.

Started

Feb 2025

Finished

Aug 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18- 60 years of either gender. * Diagnosed with melasma based on clinical examination and Wood's lamp assessment. Exclusion Criteria: * Pregnant or lactating women. * Patients with a history of hypersensitivity to any study medication components. * Patients currently on other melasma treatments or those with other dermatologic conditions affecting pigmentation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma

Contacts and locations

Locations

  • JPMC

    Karachi, Sindh, 7550, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.